Synergy Pharma Cmn (SGYP) 4.11 $SGYP
Synergy Pharmaceuticals to Present at Canaccord Genuity 36th Annual Growth Conference
BusinessWire - 2 hrs 3 mins ago
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced Marino Garcia, the company's EVP and Chief Strategy Officer, will present a corporate update at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016 at 10:00 a.m. Eastern Time at the InterContinental in Boston, Massachusetts.
SGYP: 4.11 (+0.03)
Herbalife and Ironwood advance; Infosys and Fairmount drop
AP - Fri Jul 15, 3:11PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
SGYP: 4.11 (+0.03), HLF: 67.30 (-0.71), FMSA: 6.39 (-0.46), IRWD: 14.25 (+0.12), CCL: 46.59 (-0.13), C: 43.75 (-0.06), WFC: 47.87 (-0.10), INFY: 16.56 (+0.13)
Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program
BusinessWire - Fri Jul 15, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced it has reached the Food and Drug Administration (FDA) mid-cycle review milestone for the plecanatide new drug application (NDA) in chronic idiopathic constipation (CIC). Additionally, the company is providing an update on the ongoing irritable bowel syndrome with constipation (IBS-C) program.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin
BusinessWire - Tue May 24, 12:36PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), replicated the pH-dependent activity of the body's naturally occurring gastrointestinal (GI) peptide - uroguanylin. Uroguanylin plays an important role in supporting regular bowel function through its activation of the intestinal guanylate cyclase C (GC-C) receptor.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sun May 22, 11:30AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, the company's first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sat May 21, 11:31AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional data from two pivotal phase 3 clinical trials (Study-00 and Study-03) evaluating the efficacy and safety of plecanatide, a once-daily oral tablet, in treating patients with chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016
BusinessWire - Mon May 16, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present data on plecanatide, the first uroguanylin analog being evaluated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), at Digestive Disease Week 2016 in San Diego, May 21-24.
SGYP: 4.11 (+0.03)
Synergy Pharma reports 1Q loss
Automated Insights - Tue May 10, 5:20PM CDT
NEW YORK (AP) _ Synergy Pharmaceuticals Inc. (SGYP) on Tuesday reported a loss of $59.9 million in its first quarter.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results and Business Update
BusinessWire - Tue May 10, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2016.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Inc. Announces Closing of $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Mon May 09, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has closed a registered direct offering of $89.8 million of common stock at a price of $3.00 per share.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Thu May 05, 7:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has entered into definitive agreements with certain institutional investors to sell 29,948,334 shares of common stock at a price of $3.00 per share.
SGYP: 4.11 (+0.03)
Why Synergy Pharmaceuticals Shares Jumped 15.4% in April
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 3:01PM CDT
Image source: Synergy Pharmaceuticals. What: After the FDA officially accepted a filing for approval of its lead product candidate, shares of Synergy Pharmaceuticals were sent soaring 15.4% last month, according to data from S&P Global...
SGYP: 4.11 (+0.03), AGN: 255.14 (+2.19), IRWD: 14.25 (+0.12)
These Stocks Are Starting To Catch Wall Street's Attention
ACCESSWIRE - Fri Apr 29, 8:35AM CDT
NEW YORK, NY / ACCESSWIRE / April 29, 2016 / InvestmentResearchReport.com is a small cap publication that uncovers extremely undervalued potential investment opportunities that have been overlooked by everyone else. Today we are taking a look at five companies which we believe could provide investors with potential upside volatility in the near term.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer
BusinessWire - Wed Apr 27, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Gary L. Sender has resigned as the company's Chief Financial Officer for personal reasons, effective April 30, 2016. Bernard F. Denoyer, who has served as Senior Vice President of Finance and Secretary at Synergy since 2008, will assume responsibilities as Principal Financial Officer.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
BusinessWire - Tue Apr 26, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company is scheduled to present a corporate update at the 41st Annual Deutsche Bank Health Care Conference on Wednesday, May 4,2016 at 2:50 p.m. Eastern Time.
SGYP: 4.11 (+0.03), DB: 13.17 (-0.27)
Global Constipation Market: Vast Opportunity for New Drug Entry - Key Players are AstraZeneca, Ironwood Pharmaceuticals & Synergy Pharmaceuticals - Research and Markets
BusinessWire - Fri Apr 22, 5:18AM CDT
Research and Markets has announced the addition of the "Global Constipation Market Report: 2016 Edition" report to their offering.
SGYP: 4.11 (+0.03), IRWD: 14.25 (+0.12)
What's Behind Synergy Pharmaceuticals' Soaring Shares Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 3:03PM CDT
Image source: Synergy Pharmaceuticals. What: After reporting that the FDA has officially accepted its application for the approval of plecanatide, shares of Synergy Pharmaceuticals are gaining 10.5% at 3:30 p.m. EDT today. So what:...
SGYP: 4.11 (+0.03), AGN: 255.14 (+2.19), IRWD: 14.25 (+0.12)
These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.24 (unch), SGYP: 4.11 (+0.03), HRTX: 18.56 (+1.94), RPRX: 2.05 (-0.07)
Synergy Pharmaceuticals Announces Acceptance of New Drug Application for Plecanatide, a Novel Uroguanylin Analog, in Chronic Idiopathic Constipation
BusinessWire - Tue Apr 19, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced the U.S. Food and Drug Administration (FDA) has determined that the company's New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC) is sufficiently complete to permit a substantive review. The FDA Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017.
SGYP: 4.11 (+0.03)
Why Are These 4 Stocks So Volatile Today?
ACCESSWIRE - Mon Apr 11, 9:31AM CDT
These Small Cap Stocks Are Getting Major Attention Today
SGYP: 4.11 (+0.03), CANF: 2.11 (+0.01), OMEX: 2.93 (-0.02), MNKD: 1.00 (+0.01)
Synergy Pharmaceuticals to Present at Canaccord Genuity 36th Annual Growth Conference
BusinessWire - 2 hrs 3 mins ago
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced Marino Garcia, the company's EVP and Chief Strategy Officer, will present a corporate update at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016 at 10:00 a.m. Eastern Time at the InterContinental in Boston, Massachusetts.
SGYP: 4.11 (+0.03)
Herbalife and Ironwood advance; Infosys and Fairmount drop
AP - Fri Jul 15, 3:11PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
SGYP: 4.11 (+0.03), HLF: 67.30 (-0.71), FMSA: 6.39 (-0.46), IRWD: 14.25 (+0.12), CCL: 46.59 (-0.13), C: 43.75 (-0.06), WFC: 47.87 (-0.10), INFY: 16.56 (+0.13)
Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program
BusinessWire - Fri Jul 15, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced it has reached the Food and Drug Administration (FDA) mid-cycle review milestone for the plecanatide new drug application (NDA) in chronic idiopathic constipation (CIC). Additionally, the company is providing an update on the ongoing irritable bowel syndrome with constipation (IBS-C) program.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin
BusinessWire - Tue May 24, 12:36PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), replicated the pH-dependent activity of the body's naturally occurring gastrointestinal (GI) peptide - uroguanylin. Uroguanylin plays an important role in supporting regular bowel function through its activation of the intestinal guanylate cyclase C (GC-C) receptor.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sun May 22, 11:30AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, the company's first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sat May 21, 11:31AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional data from two pivotal phase 3 clinical trials (Study-00 and Study-03) evaluating the efficacy and safety of plecanatide, a once-daily oral tablet, in treating patients with chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016
BusinessWire - Mon May 16, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present data on plecanatide, the first uroguanylin analog being evaluated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), at Digestive Disease Week 2016 in San Diego, May 21-24.
SGYP: 4.11 (+0.03)
Synergy Pharma reports 1Q loss
Automated Insights - Tue May 10, 5:20PM CDT
NEW YORK (AP) _ Synergy Pharmaceuticals Inc. (SGYP) on Tuesday reported a loss of $59.9 million in its first quarter.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results and Business Update
BusinessWire - Tue May 10, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2016.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Inc. Announces Closing of $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Mon May 09, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has closed a registered direct offering of $89.8 million of common stock at a price of $3.00 per share.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Thu May 05, 7:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has entered into definitive agreements with certain institutional investors to sell 29,948,334 shares of common stock at a price of $3.00 per share.
SGYP: 4.11 (+0.03)
Why Synergy Pharmaceuticals Shares Jumped 15.4% in April
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 3:01PM CDT
Image source: Synergy Pharmaceuticals. What: After the FDA officially accepted a filing for approval of its lead product candidate, shares of Synergy Pharmaceuticals were sent soaring 15.4% last month, according to data from S&P Global...
SGYP: 4.11 (+0.03), AGN: 255.14 (+2.19), IRWD: 14.25 (+0.12)
These Stocks Are Starting To Catch Wall Street's Attention
ACCESSWIRE - Fri Apr 29, 8:35AM CDT
NEW YORK, NY / ACCESSWIRE / April 29, 2016 / InvestmentResearchReport.com is a small cap publication that uncovers extremely undervalued potential investment opportunities that have been overlooked by everyone else. Today we are taking a look at five companies which we believe could provide investors with potential upside volatility in the near term.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer
BusinessWire - Wed Apr 27, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Gary L. Sender has resigned as the company's Chief Financial Officer for personal reasons, effective April 30, 2016. Bernard F. Denoyer, who has served as Senior Vice President of Finance and Secretary at Synergy since 2008, will assume responsibilities as Principal Financial Officer.
SGYP: 4.11 (+0.03)
Synergy Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
BusinessWire - Tue Apr 26, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company is scheduled to present a corporate update at the 41st Annual Deutsche Bank Health Care Conference on Wednesday, May 4,2016 at 2:50 p.m. Eastern Time.
SGYP: 4.11 (+0.03), DB: 13.17 (-0.27)
Global Constipation Market: Vast Opportunity for New Drug Entry - Key Players are AstraZeneca, Ironwood Pharmaceuticals & Synergy Pharmaceuticals - Research and Markets
BusinessWire - Fri Apr 22, 5:18AM CDT
Research and Markets has announced the addition of the "Global Constipation Market Report: 2016 Edition" report to their offering.
SGYP: 4.11 (+0.03), IRWD: 14.25 (+0.12)
What's Behind Synergy Pharmaceuticals' Soaring Shares Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 3:03PM CDT
Image source: Synergy Pharmaceuticals. What: After reporting that the FDA has officially accepted its application for the approval of plecanatide, shares of Synergy Pharmaceuticals are gaining 10.5% at 3:30 p.m. EDT today. So what:...
SGYP: 4.11 (+0.03), AGN: 255.14 (+2.19), IRWD: 14.25 (+0.12)
These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.24 (unch), SGYP: 4.11 (+0.03), HRTX: 18.56 (+1.94), RPRX: 2.05 (-0.07)
Synergy Pharmaceuticals Announces Acceptance of New Drug Application for Plecanatide, a Novel Uroguanylin Analog, in Chronic Idiopathic Constipation
BusinessWire - Tue Apr 19, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced the U.S. Food and Drug Administration (FDA) has determined that the company's New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC) is sufficiently complete to permit a substantive review. The FDA Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017.
SGYP: 4.11 (+0.03)
Why Are These 4 Stocks So Volatile Today?
ACCESSWIRE - Mon Apr 11, 9:31AM CDT
These Small Cap Stocks Are Getting Major Attention Today
SGYP: 4.11 (+0.03), CANF: 2.11 (+0.01), OMEX: 2.93 (-0.02), MNKD: 1.00 (+0.01)
